Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357706 | 0.90 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL19576141 | 0.88 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356953 | 0.88 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL5263034 | 0.87 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356214 | 0.86 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356154 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL357282 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL30230513 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL352815 | 0.80 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677655 | 0.78 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3153514-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-1761540-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2612862-B1 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2016-03-17 | — | — | US | disclosed |
| US-9149477-B2 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2612862-A2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130116266-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8207153-B2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-7932260-B2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1761540-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-20130116266-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PI4KA, PI4KB, PIK3CD | PIK3CD 3/4885PIK3CG 16/4885PIK3CB 8/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 3/4885 |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.